國家衛生研究院 NHRI:
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 848363      在线人数 : 995
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧:
  • 您可在西文检索词汇前后加上"双引号",以获取较精准的检索结果
  • 若欲以作者姓名搜寻,建议至进阶搜寻限定作者字段,可获得较完整数据
  • 进阶搜寻
    主页登入上传说明关于NHRI管理 到手机版

    子类别

    期刊論文 [19/20]
    會議論文/會議摘要 [7/11]

    社群统计


    近3年内发表的文件:0(0.00%)
    含全文笔数:26(83.87%)

    文件下载次数统计
    下载大于0次:26(100.00%)
    下载大于100次:26(100.00%)
    全文下载总次数:23590(0.44%)

    最后更新时间: 2024-11-28 15:45

    上传排行

    数据加载中.....

    下载排行

    数据加载中.....

    RSS Feed RSS Feed
    跳至:
    或输入年份:
    由新到旧排序 由最旧的开始

    显示项目1-25 / 31. (共2页)
    1 2 > >>
    每页显示[10|25|50]项目

    日期题名關聯
    2017-05 A phase I dose escalation study of SCBO1A, a micro tubular inhibitor with vascular disrupting activity, in patients with advanced solid tumors refractory to standard therapy Journal of Clinical Oncology. 2017 May;35(Suppl. 15):Meeting Abstract 2531.
    2016-02 Phase I dose-escalation study of sorafenib plus S-1 in refractory solid tumors Journal of Clinical Oncology. 2016 Feb;34(4, Suppl.):Meeting Abstract 745.
    2013-05 Concurrent chemoradiotherapy with cetuximab plus twice-weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma Journal of Clinical Oncology. 2013 May;31(15 Suppl.):Abstract number 10619.
    2013-01 Randomised clinical trial: Comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma Alimentary Pharmacology and Therapeutics. 2013 Jan;37(1):62-73.
    2012-09 Early data from a phase I study of nintedanib (BIBF1120) in Asian patients with advanced hepatocellular carcinoma Annals of Oncology. 2012 Sep;23(Suppl. 9):246-247.
    2012-02 Phase I study of biweekly liposome irinotecan (PEP02, MM-398) in metastatic colorectal cancer failed on firstline oxaliplatin-based chemotherapy Journal of Clinical Oncology. 2012 Feb;30(4):613.
    2011-12-15 Combination of arsenic trioxide and BCNU synergistically triggers redox-mediated autophagic cell death in human solid tumors Free Radical Biology and Medicine. 2011 Dec 15;51(12):2195-2209.
    2011-10 Novel feedback inhibition of surface antigen synthesis by Mammalian Target of Rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapy Hepatology. 2011 Oct;54(4):1199-1207.
    2011-04 Activation of Akt/FoxO axis confers resistance to cisplatin in human nasopharyngeal carcinomas Cancer Research. 2011 Apr;71:Abstract number 1701.
    2011-02 Concurrent chemoradiotherapy with cetuximab plus twice-weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma Journal of Clinical Oncology. 2011 Feb;29(Suppl. 4):Abstract Number 79.
    2010-06 Randomized, phase 1 study of everolimus in patients with advanced hepatocellular carcinoma Annals of Oncology. 2010 Jun;21(Suppl. 6):27.
    2009-12 Alpha-fetoprotein response in advanced hepatocellular carcinoma receiving cytostatic agent Journal of Clinical Oncology. 2009 Dec;27(36):e271.
    2009-11 Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer Cancer Chemotherapy and Pharmacology. 2009 Nov;64(6):1173-1179.
    2009-09 Synergistic augmentation of arsenic trioxide-induced cytotoxicity by BCNU through reactive oxygen species-related autophagic pathway in human solid tumors EJC Supplements. 2009 Sep;7(3):16.
    2009-05-20 Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC) Journal of Clinical Oncology. 2009 May 20;27(15s):Abstract number 4587.
    2007-11-15 Tamoxifen accelerates proteasomal degradation of O-6-methylguanine DNA methyltransferase in human cancer cells International Journal of Cancer. 2007 Nov;121(10):2293-2300.
    2007-03-01 Mitochondria-mediated and p53-associated apoptosis induced in human cancer cells by a novel selenophene derivative, D-501036 Biochemical Pharmacology. 2007 Mar;73(5):610-619.
    2007-01 D-501036, a novel selenophene-based triheterocycle derivative, exhibits potent in vitro and in vivo antitumoral activity which involves DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation Molecular Cancer Therapeutics. 2007 Jan;6(1):193-202.
    2006-11 Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma Cancer Chemotherapy and Pharmacology. 2006 Nov;58(5):654-664.
    2006-11 D-501036, a novel selenophene-base triheterocycle derivative exhibits potent in vitro and in vivo anti-tumoral activity, which involves DNA-damage and ATM activation EJC Supplements. 2006 Nov;4(12):92.
    2006-10 Inhibition of cell growth and nuclear factor-kappa B activity in pancreatic cancer cell lines by a tylophorine analogue, DCB-3503 Molecular Cancer Therapeutics. 2006 Oct;5(10):2484-2493.
    2006-10 Abrogation of skin disease in lupus-prone MRL/Fas(lpr) mice by means of a novel tylophorine analog Arthritis and Rheumatism. 2006 Oct;54(10):3277-3283.
    2006-05 Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer Journal of Gastroenterology and Hepatology. 2006 May;21(5):874-879.
    2006-03 Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer Journal of Gastroenterology and Hepatology. 2006 Mar;21(3):531-536.
    2005-12 Pulmonary embolism after transcatheter arterial chemoembolization European Journal of Cancer Care. 2005 Dec;14(5):440-442.

    显示项目1-25 / 31. (共2页)
    1 2 > >>
    每页显示[10|25|50]项目

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈